Linda Chen

Memorial Sloan Kettering Cancer Center

Papers

1

Total Citations

57

H-Index

1

About

Dr. Linda Chen is a leading voice in the evolving landscape of head and neck oncology, with a primary focus on treatment deintensification for human papillomavirus (HPV)-associated oropharyngeal cancer. Her seminal 2022 review, "Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus‐associated oropharyngeal cancer," has garnered 57 citations, establishing her as a key synthesizer of a critical clinical debate. Dr. Chen’s major contribution lies in navigating the delicate balance between reducing the severe, long-term toxicities of chemoradiation—such as dysphagia and xerostomia—while preserving the excellent survival outcomes seen in HPV-positive patients. Her work systematically outlines emerging strategies, including de-escalated radiation doses and the omission of chemotherapy, providing a roadmap for future clinical trials. By highlighting both areas of consensus and persistent controversy, Dr. Chen has helped shape a more nuanced, patient-centered approach to care. Her research is instrumental for clinicians and researchers striving to improve quality of life without compromising oncologic control, marking her as a pivotal figure in the shift toward personalized, less morbid treatments for this rising cancer.

Research Focus

Key Achievements

1
H-Index
1
Papers
57
Total Citations
57
Avg Citations/Paper
🏆 Most Cited Paper
Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus‐associated oropharyngeal cancer
57 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 19
🏛 Institutions: Memorial Sloan Kettering Cancer Center

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago